Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 65Gastrointestinal 46Thoracic 36Dermatologic 28Breast 25Gynecologic 23Head & Neck 21Lymphoid 14Tumor-Agnostic 13Other solid neoplasm 10Sarcoma 9CNS 9Endocrine 7Other hematologic neoplasm 5NET 4Plasma cell 1Myeloid 1

Conditions

Uveal Melanoma 1Primary Myelofibrosis 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1

Interventions

Cyclophosphamide 259fludarabine phosphate 232Azacitidine 180fludarabine 179Busulfan 174Cytarabine 154Mycophenolic Acid 147Tacrolimus 145Whole-Body Irradiation 141Imatinib Mesylate 141Peripheral Blood Stem Cell Transplantation 139Cyclosporine 110Antilymphocyte Serum 108Melphalan 106Methotrexate 105Filgrastim 101Decitabine 98nilotinib 82venetoclax 77ruxolitinib 72Granulocyte Colony-Stimulating Factor 66Stem Cell Transplantation 62Dasatinib 62Thiotepa 60Radiotherapy 60thymoglobulin 52Specimen Handling 49Etoposide 49Clofarabine 46Cord Blood Stem Cell Transplantation 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × avelumab × Myeloid × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡